文献速递浆细胞疾病淋巴瘤MDS 与骨髓增殖性肿瘤

国际戈谢病集团戈谢病登记研究中2123例1型戈谢病成人患者的癌症风险与丙种球蛋白病

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
PubMed 文献 · Am J Hematol · 2022-08-24

该国际观察性研究纳入2123例1型戈谢病(GD1)患者,比较其癌症总体及各类恶性肿瘤风险与美国人群(SEER数据库)。结果显示血液系统恶性肿瘤风险较一般人群高4倍以上,非霍奇金淋巴瘤约3倍、多发性骨髓瘤约9倍;MGUS在年轻患者中年龄别发病率意外地高;MGUS诊断后10年多发性骨髓瘤累积发病率为7.9%,与一般人群相当。实体瘤中肝、肾、黑色素瘤、乳腺癌风险升高,结直肠癌、前列腺癌、肺癌风险降低。

要点

  • GD1患者血液系统恶性肿瘤风险较一般人群高4倍以上,多发性骨髓瘤约9倍。
  • MGUS在年轻GD1患者中年龄别发病率意外地高。
  • 实体瘤中肝癌2.9倍、肾癌2.8倍、黑色素瘤2.5倍、乳腺癌1.4倍风险升高。

核心结论

  • GD1患者血液系统恶性肿瘤风险较一般人群高4倍以上,其中非霍奇金淋巴瘤约3倍、多发性骨髓瘤约9倍。
  • MGUS诊断后10年多发性骨髓瘤累积发病率为7.9%,与一般人群相当。
  • GD1患者肝癌、肾癌、黑色素瘤、乳腺癌风险高于一般美国人群,结直肠癌、前列腺癌、肺癌风险低于预期。
  • 这些发现支持对GD1患者进行个体化恶性肿瘤监测及对MGUS等前驱病变监测的建议,并引出葡萄糖神经酰胺及相关鞘脂在癌症生物学中作用的重要问题。

研究设计与样本

  • 国际观察性研究,国际 cooperative 戈谢病集团戈谢病登记研究(Clinicaltrials.gov:NCT00358943),纳入2123例1型戈谢病患者。
  • 癌症总体及各类型恶性肿瘤风险与美国人群(监测、流行病学和最终结果数据库)比较。
  • 通过评估从意义未明的单克隆丙种球蛋白病(MGUS)诊断进展至多发性骨髓瘤(MM)来确定丙种球蛋白病的自然史。

主要发现

  • 血液系统恶性肿瘤风险较一般人群高4倍以上:非霍奇金淋巴瘤约3倍,多发性骨髓瘤约9倍。
  • MGUS在年轻患者中年龄别发病率意外地高。
  • MGUS诊断后10年多发性骨髓瘤累积发病率为7.9%,与一般人群相当。
  • 实体瘤风险较一般美国人群:肝癌2.9倍、肾癌2.8倍、黑色素瘤2.5倍、乳腺癌1.4倍。
  • 结直肠癌、前列腺癌和肺癌风险低于预期。

临床怎么用

  • 原文结论指出这些发现支持对GD1患者进行个体化恶性肿瘤监测及对MGUS等MM前驱病变监测的建议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are numerous reports of cancers in Gaucher disease (GD) from mostly small single-center studies; however, precise risk estimates and cancer types involved have not been delineated. We conducted a study involving 2123 patients with GD type 1 (GD1) to assess the incidence of hematological malignancies, gammopathies, and solid tumors in an international observational study, the International Cooperative Gaucher Group Gaucher Registry (Clinicaltrials.gov: NCT00358943). Risk for cancer overall and for each type of malignancy was compared to the United States (US) population using the Surveillance, Epidemiology, and End Results database. Natural history of gammopathy was determined through assessing the progression from a diagnosis of monoclonal gammopathy of unknown significance (MGUS) to multiple myeloma (MM). Risk for hematological malignancies was more than four times higher than expected compared to the general population: non-Hodgkin lymphoma was approximately three times higher; MM was approximately nine times higher. Age-specific incidence rates of MGUS were unexpectedly high among younger patients. The 10-year cumulative incidence of MM after diagnosis of MGUS was 7.9%, comparable to the general population. Compared to the general US population, GD1 patients were at higher risk for solid malignancies of liver (2.9 times), kidney (2.8 times), melanoma (2.5 times), and breast (1.4 times). Colorectal, prostate, and lung cancer risks were lower than expected. These findings help advance care of patients with GD1 by supporting recommendations for individualized monitoring for malignancies and antecedents such as MGUS for MM and provoke important questions of the role of glucosylceramide and related sphingolipids in cancer biology.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rosenbloom BE, Cappellini MD, Weinreb NJ, et al. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. Am J Hematol. 2022. PMID: 36054609. doi:10.1002/ajh.26675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。